

Severe Adverse Effects

- seizures / Delayed / 0.9-5.6
- AV block / Early / 4.0-4.7
- bradycardia / Rapid / 3.0-3.0
- skin cancer / Delayed / 2.0-2.0
- macular edema / Delayed / 0.5-1.5
- cervical cancer / Delayed / Incidence not known
- hemolytic anemia / Delayed / Incidence not known
- visual impairment / Early / Incidence not known
- hepatotoxicity / Delayed / Incidence not known
- hepatic failure / Delayed / Incidence not known
- stroke / Early / Incidence not known
- angioedema / Rapid / Incidence not known
- progressive multifocal leukoencephalopathy / Delayed / Incidence not known
- new primary malignancy / Delayed / Incidence not known
- lymphoma / Delayed / Incidence not known

Moderate Adverse Effects

- elevated hepatic enzymes / Delayed / 15.0-15.0
- dyspnea / Early / 9.0-9.0
- hypertension / Early / 8.0-8.0
- lymphopenia / Delayed / 7.0-7.0
- migraine / Early / 6.0-6.0
- blurred vision / Early / 4.0-4.0
- leukopenia / Delayed / 2.0-2.0
- actinic keratosis / Delayed / 2.0-2.0
- atopic dermatitis / Delayed / 0-1.0 ^[1]

[1] - Gilenya (fingolimod) dose, indications, adverse effects, interactions... from PDR.net
<https://www.pdr.net/drug-summary/Gilenya-fingolimod-432.5709#11>, accessed: 2021-11-28

